Description
Chemical Identity
CJC-1295 without DAC analytical reference compound. Molecular weight 3367.9 Da. Also known as: Modified GRF(1-29), Mod GRF 1-29, GRF(1-29) NH2. Research status: Preclinical.
Research Overview
CJC-1295 without DAC (Modified GRF 1-29) is a synthetic 29-amino acid analog of growth hormone-releasing hormone with four amino acid substitutions for enhanced stability. Unlike its DAC-conjugated counterpart, it has a short half-life of approximately 30 minutes, producing discrete GH pulses that closely mimic natural physiology.
CJC-1295 without DAC functions as a selective agonist of the GHRH receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary gland. Binding to the GHRH-R activates the Gs-adenylate cyclase-cAMP-PKA signaling cascade, which promotes both the transcription of the growth hormone gene and the exocytotic release of stored GH-containing secretory granules.
The mechanism is identical to that of its DAC-conjugated counterpart and of native GHRH. The critical pharmacological difference lies in the duration of receptor engagement. Without albumin binding, the peptide is cleared from the circulation within approximately 30 minutes, producing a brief burst of GHRH receptor activation followed by rapid return to baseline. This creates a discrete, time-limited GH pulse that closely mimics the endogenous pulsatile pattern of GH secretion.
Key published studies on CJC-1295 without DAC include: “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults” (Journal of Clinical Endocrinology and Metabolism, 2006); “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse” (American Journal of Physiology – Endocrinology and Metabolism, 2006). These findings should be interpreted within the context of the experimental models and conditions described in each publication.
Research Context
CJC-1295 without DAC, commonly referred to as Modified GRF(1-29) or Mod GRF 1-29, is a synthetic 29-amino acid peptide analog of growth hormone-releasing hormone (GHRH). It represents the active peptide component of the CJC-1295 platform without the Drug Affinity Complex (DAC) moiety that enables albumin binding. This distinction is pharmacologically critical: without the DAC, the peptide has a plasma half-life of approximately 30 minutes rather than 6 to 8 days, fundamentally changing its pharmacokinetic and pharmacodynamic profile.
The peptide is based on the first 29 amino acids of human GHRH, which constitute the minimum fragment required for full biological activity at the GHRH receptor. Four strategic amino acid substitutions at positions 2, 8, 15, and 27 have been incorporated to improve metabolic stability, particularly resistance to cleavage by dipeptidyl peptidase IV (DPP-IV), the primary enzyme responsible for rapid inactivation of native GHRH.
Modified GRF(1-29) is widely used in research settings, often in combination with ghrelin-mimetic peptides such as ipamorelin or GHRP-6, to study pulsatile growth hormone stimulation. The combination of GHRH analog and ghrelin-mimetic produces synergistic GH release that exceeds the effect of either compound alone, as they act through complementary receptor pathways.
Specifications
| Sequence | YADAIFTQSYRKVLAQLSARKLLQDILSR |
| Molecular Weight | 3367.9 Da |
| Molecular Formula | C152H252N44O42 |
| CAS Number | 863288-34-0 |
| Purity | >=98% (HPLC) |
| Appearance | White to off-white lyophilized powder |
| Format | Lyophilized powder, sterile filtered |
| Solubility | Soluble in bacteriostatic water, sterile water, or normal saline |
| Storage | Store at -20°C (lyophilized). Reconstituted: 2-8°C, use within 30 days |
| Shipping | Ambient temperature (stable in lyophilized form) |
Each lot is accompanied by a Certificate of Analysis (COA) documenting purity, identity, and endotoxin testing results.
Research Applications
CJC-1295 without DAC reference compound has been documented in the published scientific literature across the following in vitro and preclinical research areas:
- Growth hormone axis research
- Pulsatile GH stimulation studies
- Body composition research
- Combination protocols with GHRP peptides
Researchers are advised to consult the primary literature for detailed experimental protocols, concentrations, and conditions relevant to their specific area of investigation involving CJC-1295 without DAC.
Storage and Handling
CJC-1295 without DAC is supplied as a lyophilized powder and should be stored at -20°C upon receipt for long-term stability. Protect from light, moisture, and repeated temperature fluctuations. Allow the sealed vial to equilibrate to room temperature before opening to prevent condensation and moisture absorption.
For reconstitution, add sterile water or an appropriate buffer slowly along the vial wall to avoid foaming. Gently swirl to dissolve — do not vortex. Reconstituted CJC-1295 without DAC solutions should be stored at 2-8°C and used within 30 days. Aliquoting is recommended to minimize freeze-thaw cycles. Consult the Safety Data Sheet (SDS) for detailed handling and disposal guidance.
For laboratory research use only (in vitro). Not for human or animal use. Not for diagnostic, therapeutic, or clinical purposes. CJC-1295 without DAC is supplied as an analytical reference compound for use by qualified research personnel at accredited institutions. Prescott Bio Canada does not provide guidance on administration, dosing, or use in living organisms.